Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCR4 CAR T Cells for CCR4 Expressing T-cell Malignancies
NCT07055477Phase 1Suspended
- Sponsor
- National Cancer Institute
- Start
- Sep 2025
- Primary completion
- Jun 2044
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous CCR4 CAR T cells in mature T-cell neoplasm (PTCL) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Safety profile of administering autologous CCR4 CAR T cells at 12 weeks. Started Sep 2025; status: suspended.
02
Drugs
autologous CCR4 CAR T cells
03
Conditions
mature T-cell neoplasm (PTCL)
Beyond the preview
Go deeper on NCT07055477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055477.